BiotechTube

Tedizolid phosphate + Linezolid

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumonia

Conditions

Pneumonia

Trial Timeline

Jan 6, 2014 → Jun 22, 2018

NCT ID
NCT02019420

About Tedizolid phosphate + Linezolid

Tedizolid phosphate + Linezolid is a phase 3 stage product being developed by Merck for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02019420. Target conditions include Pneumonia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02019420Phase 3Completed

Competing Products

20 competing products in Pneumonia

See all competitors
ProductCompanyStageHype Score
CAL02 Low-dose + CAL02 High-dose + PlaceboCombioxinPhase 1
25
tacrolimusAstellas PharmaPre-clinical
23
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
52
doripenemJohnson & JohnsonApproved
85
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
52
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
Ceftazidime-avibactamAbbViePhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
77
IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85